07:00 , Oct 18, 2010 |  BC Week In Review  |  Clinical News

PF-00299804: Preliminary Phase II data

Preliminary data from the open-label, international Phase II A7471017 trial in 74 patients with previously untreated advanced NSCLC showed that once-daily PF-00299804 produced PFS rates of 78%, 73% and 62% at 4, 6 and 9...
07:00 , Oct 18, 2010 |  BC Week In Review  |  Clinical News

PF-00299804: Phase II data

An international Phase II trial in 188 patients who had failed 1 or 2 prior chemotherapy regimens showed that 45 mg once-daily PF-00299804 met the primary endpoint of significantly increasing median PFS vs. 150 mg...
07:00 , Jul 29, 2010 |  BC Innovations  |  Targets & Mechanisms

Attacking cancer's secretive side

Researchers from the Weizmann Institute of Science have shown that antibodies against epidermal growth factor receptor ligands from pancreatic tumors boosted the effectiveness of Eli Lilly and Co.'s Gemzar gemcitabine, one of the two drugs...
07:00 , Oct 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Multiple sclerosis (MS) ...
08:00 , Jan 8, 2009 |  BC Innovations  |  Targets & Mechanisms

Gazing deeper into cancer

Three recent genomic studies in glioblastoma multiforme,1 acute myeloid leukemia2 and lung adenocarcinoma3reveal potential new drug targets and provide a next step toward personalized, whole genome-based cancer diagnostics. Genomic sequencing could provide more robust data...
08:00 , Dec 22, 2008 |  BioCentury  |  Regulation

The case for retrospection

Having fallen behind European regulators and U.S. clinical practice in stratifying cancer patients with K-Ras mutations for treatment with Erbitux and Vectibix, FDA last week convened an advisory panel meeting that gave it cover to...
07:00 , Oct 16, 2000 |  BC Week In Review  |  Company News

Enchira, University of Texas M.D. Anderson Cancer Center deal

The partners will develop ligands that block epidermal growth factor receptors. ENBC will use its directed evolution technology to create ligands that suppress overexpression of the EGFR and HER-2/neu receptors associated with metastatic cancers,...
08:00 , Nov 15, 1993 |  BC Week In Review  |  Clinical News

Seragen preclinical data

In an animal model of restenosis, the agent stopped the overgrowth of smooth muscle cells lining blood vessels. In rats given angioplasty, local application of the fusion toxin stopped restenosis, with significant difference (p <0.05)...